Celgene Corp. (CELG)

97.15
0.15 0.15
NASDAQ : Health Technology
Prev Close 97.30
Open 97.38
Day Low/High 97.00 / 97.89
52 Wk Low/High 58.59 / 97.15
Volume 4.52M
Avg Volume 6.79M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 68.06B
EPS 5.70
P/E Ratio 14.73
Div & Yield N.A. (N.A)
Remember That Bumps in the Road Are Normal: Market Recon

Remember That Bumps in the Road Are Normal: Market Recon

The forces that artificially impacted the marketplace return to normal; so will the marketplace itself.

Don't Panic About Biotech

Don't Panic About Biotech

Diversification is absolutely critical when investing in this sector.

My (Brief) Takeaways and Observations

With thirty minutes to go: * Watching CNBC and the rest of the business media, one would conclude that "everyone is in the pool." It is, as one talking head just declared..."a buy/buy scenario." (Enough said/written). * The bond market's decline was...

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.

Celgene Cut to Neutral at Baird

Celgene: Look Beyond Any Short-Term Weakness

Celgene: Look Beyond Any Short-Term Weakness

CELG could dip and then post longer-term gains.

'Zone' In on This Celgene Setup

'Zone' In on This Celgene Setup

Look at this recent pullback as an opportunity for a buy-side entry.

Are You Patient Enough With Options?

Are You Patient Enough With Options?

You have options when trading options, so don't give up your leverage or advantage too soon.

My Takeaways and Observations

"While options can give market participants the protection they are intended to provide, they can also increase the degree of a counter move, once it gets going, as those who wrote the protection scramble to unwind their own exposure." -- Kass Diary...

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."

Cramer: Trend Appears to Be 'If It's Up, Buy It'

Cramer: Trend Appears to Be 'If It's Up, Buy It'

Where is this coming from?

Celgene New Top Pick at RBC

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I've Prepared for Hurricane Irma -- and a Market Pullback

As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.

How I'm Prepared for Irma -- and a Pullback

How I'm Prepared for Irma -- and a Pullback

As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks

This team is playoff-ready and built for the ages.

Cramer: There Should Be More Takeovers Where These Came From

Cramer: There Should Be More Takeovers Where These Came From

Buying's good for the acquirers, which should give other companies ideas.

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

My Takeaways and Observations

"Yeah, well, that's just, like, your opinion, man." -- The Dude, The Big Lebowski Strikes and gutters today -- in a market characterized by winners and losers and weakening breadth. Ups and downs.    Amazon's shares may be signaling there is no fun,...

Cramer: Random Movement Is Exactly That

Cramer: Random Movement Is Exactly That

Nothing's happening, but that doesn't mean you have to make something happen.

Be Cautious in Case of a Second-Half Hiccup

Be Cautious in Case of a Second-Half Hiccup

The market seems fully valued, so I'm building up cash as we head into historically volatile months.

Back to Basics in Biotech

Back to Basics in Biotech

Stop losses do not work in this part of the market.

Back to Basics in Biotech

Back to Basics in Biotech

Stop losses do not work in this part of the market.

Looking to Buy Some Celgene? Now's a Good Time

Looking to Buy Some Celgene? Now's a Good Time

CELG looks like it has a promising future, according to the charts.

My Takeaways and Observations (Early Edition)

The story's in the past with nothin' to recall, I've got my life to live and I don't need you at all. The roller-coaster ride we took is nearly at an end, I bought my ticket with my tears, that's all I'm gonna spend. -- The Cyrkle, Red Rubber Ball M...

Here's Why I'm Valuing Value Over Growth

Here's Why I'm Valuing Value Over Growth

Multiples have become quite rich and dysfunction in Washington could end up biting the markets.

Biotech Bucking the Trend

Coming up on the two-hour mark on trading. The market is down slightly down across the board, with Nasdaq being affected by disappointing results from Starbucks and Amazon . The failure to even getting a "skinny" repeal and replacement of the Afford...

Now Up to the Plate, Today's Pinch Hitter, Bret Jensen!

It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...

Here's What Up (and Down)

After 90 minutes of trading here are some market features:   * Bonds are getting schmeissed. The 10-year U.S. note yield is close to 2.32% and the long bond is knocking on the door of 3.00%. A possible equity market headwind. * Retail still has a ni...

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.